Your browser doesn't support javascript.
loading
Minimizing the initial burst of octreotide acetate from glucose star PLGA microspheres prepared by the solvent evaporation method.
Beig, Avital; Ackermann, Rose; Wang, Yan; Schutzman, Richard; Schwendeman, Steven P.
Afiliação
  • Beig A; Department of Pharmaceutical Sciences and the Biointerfaces Institute, University of Michigan, 2800 Plymouth Road, Ann Arbor, MI 48109, United States.
  • Ackermann R; Department of Pharmaceutical Sciences and the Biointerfaces Institute, University of Michigan, 2800 Plymouth Road, Ann Arbor, MI 48109, United States.
  • Wang Y; Office of Research and Standards, Office of Generic Drugs, Center for DrugEvaluation and Research, U.S. Food and Drug Administration, 10903 New Hampshire Ave, Silver Spring, MA 20993, United States.
  • Schutzman R; Department of Pharmaceutical Sciences and the Biointerfaces Institute, University of Michigan, 2800 Plymouth Road, Ann Arbor, MI 48109, United States.
  • Schwendeman SP; Department of Pharmaceutical Sciences and the Biointerfaces Institute, University of Michigan, 2800 Plymouth Road, Ann Arbor, MI 48109, United States; Department of Biomedical Engineering, University of Michigan, 2200 Bonisteel Blvd, Ann Arbor, MI 48109, United States. Electronic address: schwende@u
Int J Pharm ; 624: 121842, 2022 Aug 25.
Article em En | MEDLINE | ID: mdl-35609832
Sandostatin long-acting release (SLAR) depot for 1-month controlled release of octreotide is a somatostatin analogue product that has been used extensively in the pharmacological treatment of acromegaly. The complexities in the SLAR coacervation manufacturing processes and the use of a unique glucose-starpoly(lactic-co-glycolic acid) (PLGA-glu) may have contributed to the lack of US FDA-approved generic products referencing SLAR in the USA. To address this challenge, we encapsulated octreotide acetate by the commonly used solvent evaporation method in microspheres of a similar composition to SLAR, including the use of a comparable PLGA-glu. Based on our previous study that identified key formulation variables to prepare octreotide acetate/PLGA-glu microspheres, including lowering initial peptide pH and introducing an annealing step post loading, here we added NaCl to the external water phase to further improve the formulation. The resulting microspheres exhibited highly similar release and stability performance in vitro to SLAR, including an exceptionally low initial burst. The very low initial burst was also confirmed by pharmacokinetics in rats. Full erosion behavior analysis (polymer MW, water uptake and mass loss) revealed a slightly faster degradation of SLAR than the solvent evaporation formulations. Analysis of kinetics of dry Tg of the formulations reflected (a) the elevated residual solvent in SLAR and was not duplicated in the solvent evaporation formulations, and (b) the slightly higher Tg of peptide loaded formulations relative to than blank microspheres, consistent with the interaction of the acetate salt of octreotide with linear PLGA chains in the PLGA-glu. These data indicate that it is possible to prepare peptide loaded microspheres by the solvent evaporation method with extraordinarily similar performance to microspheres, such as those in SLAR, that are prepared by the low-burst release coacervation method.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ácido Poliglicólico / Octreotida Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Int J Pharm Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Holanda

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Ácido Poliglicólico / Octreotida Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Int J Pharm Ano de publicação: 2022 Tipo de documento: Article País de afiliação: Estados Unidos País de publicação: Holanda